$SKGR
SK Growth Opportunities Corp

2023 Q4 Form 10-K Financial Statement

#000119312524082043 Filed on March 29, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2023 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $578.8K $2.151M $720.0K
YoY Change 106.72% 198.77% 2300.0%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $578.8K $2.151M $720.0K
YoY Change 106.72% 198.77% 2300.0%
Operating Profit -$2.151M -$717.3K
YoY Change 199.91%
Interest Expense $2.662M $10.30M $2.830M
YoY Change 20.99% 263.8%
% of Operating Profit
Other Income/Expense, Net $10.30M $2.827M
YoY Change 264.23%
Pretax Income $2.083M $8.144M $2.110M
YoY Change 8.49% 285.99% -7133.33%
Income Tax
% Of Pretax Income
Net Earnings $2.083M $8.144M $2.109M
YoY Change 8.49% 286.11% -7131.16%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.08 $0.31 $0.13
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $163.7K $163.7K $500.0K
YoY Change -67.26% -67.26%
Cash & Equivalents $163.7K
Short-Term Investments
Other Short-Term Assets $209.8K $209.8K $400.0K
YoY Change -47.56% -47.56%
Inventory
Prepaid Expenses $209.8K
Receivables
Other Receivables
Total Short-Term Assets $373.5K $373.5K $900.0K
YoY Change -59.9% -58.5%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $109.6M $109.6M $217.6M
YoY Change -49.64% -49.64%
Other Assets $0.00 $0.00 $200.0K
YoY Change -100.0% -100.0%
Total Long-Term Assets $109.6M $109.6M $217.9M
YoY Change -49.7% -49.71%
TOTAL ASSETS
Total Short-Term Assets $373.5K $373.5K $900.0K
Total Long-Term Assets $109.6M $109.6M $217.9M
Total Assets $109.9M $109.9M $218.8M
YoY Change -49.75% -49.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $107.2K $107.2K $0.00
YoY Change 4499.74%
Accrued Expenses $1.204M $1.204M $300.0K
YoY Change 300.74% 301.39%
Deferred Revenue
YoY Change
Short-Term Debt $5.620M $5.620M $5.200M
YoY Change 8.08% 8.08%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.931M $6.931M $5.500M
YoY Change 25.05% 26.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.336M $7.336M $7.300M
YoY Change 0.49% 0.49%
Total Long-Term Liabilities $7.336M $7.336M $7.300M
YoY Change 0.0% 0.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.931M $6.931M $5.500M
Total Long-Term Liabilities $7.336M $7.336M $7.300M
Total Liabilities $14.27M $14.27M $12.90M
YoY Change 10.78% 10.6%
SHAREHOLDERS EQUITY
Retained Earnings -$13.79M
YoY Change 18.48%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $95.68M $95.68M $205.9M
YoY Change
Total Liabilities & Shareholders Equity $109.9M $109.9M $218.8M
YoY Change -49.75% -49.75%

Cashflow Statement

Concept 2023 Q4 2023 2022
OPERATING ACTIVITIES
Net Income $2.083M $8.144M $2.109M
YoY Change 8.49% 286.11% -7131.16%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$289.0K -$731.7K -$1.214M
YoY Change 221.08% -39.72%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $118.6M $118.6M -$214.8M
YoY Change -155.22%
Cash From Investing Activities $118.6M $118.6M -$214.8M
YoY Change -155.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$118.6M -$118.6M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -118.3M -118.3M 216.6M
YoY Change -154.61%
NET CHANGE
Cash From Operating Activities -289.0K -731.7K -1.214M
Cash From Investing Activities 118.6M 118.6M -214.8M
Cash From Financing Activities -118.3M -118.3M 216.6M
Net Change In Cash 91.03K -351.7K 515.4K
YoY Change -201.14% -168.23%
FREE CASH FLOW
Cash From Operating Activities -$289.0K -$731.7K -$1.214M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001912461
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity Registrant Name
EntityRegistrantName
SK GROWTH OPPORTUNITIES CORPORATION
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2023 dei Entity File Number
EntityFileNumber
001-41432
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1643582
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
228 Park Avenue S #96693
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10003
CY2023 dei City Area Code
CityAreaCode
917
CY2023 dei Local Phone Number
LocalPhoneNumber
599-1622
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Public Float
EntityPublicFloat
221966400
CY2023 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2023 dei Auditor Location
AuditorLocation
New York, New York
CY2023 dei Auditor Firm
AuditorFirmId
100
CY2023Q4 us-gaap Cash
Cash
163718
CY2022Q4 us-gaap Cash
Cash
515410
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
209750
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
415866
CY2023Q4 us-gaap Assets Current
AssetsCurrent
373468
CY2022Q4 us-gaap Assets Current
AssetsCurrent
931276
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
0
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
204750
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
109573279
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
217645818
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
109573279
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
217850568
CY2023Q4 us-gaap Assets
Assets
109946747
CY2022Q4 us-gaap Assets
Assets
218781844
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
107223
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2331
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1204161
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
300481
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
380000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2023Q4 skgr Overfunding Loan
OverfundingLoan
5240000
CY2022Q4 skgr Overfunding Loan
OverfundingLoan
5240000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6931384
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5542812
CY2023Q4 skgr Deferred Underwriting And Advisory Fees
DeferredUnderwritingAndAdvisoryFees
7336000
CY2022Q4 skgr Deferred Underwriting And Advisory Fees
DeferredUnderwritingAndAdvisoryFees
7336000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7336000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7336000
CY2023Q4 us-gaap Liabilities
Liabilities
14267384
CY2022Q4 us-gaap Liabilities
Liabilities
12878812
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13794440
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11643310
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13793916
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11642786
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109946747
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
218781844
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2151130
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
717265
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-2151130
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-717265
CY2023 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
10570325
CY2022 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2805818
CY2023 skgr Fair Value Of Shares Issued Pursuant To Non Redemption Agreement
FairValueOfSharesIssuedPursuantToNonRedemptionAgreement
274826
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-20794
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10295499
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2826612
CY2023 us-gaap Net Income Loss
NetIncomeLoss
8144369
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163718
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
515410
CY2023 skgr Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2109347
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-8831
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
6792000
CY2022 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
3144000
CY2022 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
23480261
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2109347
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11642786
CY2023 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
10570325
CY2023 skgr Fair Value Of Shares Issued Pursuant To Non Redemption Agreement
FairValueOfSharesIssuedPursuantToNonRedemptionAgreement
274826
CY2023 us-gaap Net Income Loss
NetIncomeLoss
8144369
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13793916
CY2023 us-gaap Net Income Loss
NetIncomeLoss
8144369
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2109347
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-20794
CY2023 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
10570325
CY2022 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2805818
CY2023 skgr Fair Value Of Shares Issued Pursuant To Non Redemption Agreement
FairValueOfSharesIssuedPursuantToNonRedemptionAgreement
274826
CY2022 skgr Fair Value Of Shares Issued Pursuant To Non Redemption Agreement
FairValueOfSharesIssuedPursuantToNonRedemptionAgreement
0
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-410866
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
620616
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
104892
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2331
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
903680
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
121650
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-731692
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1213900
CY2023 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0
CY2022 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
214840000
CY2023 skgr Cash Withdrawn For Redemptions
CashWithdrawnForRedemptions
118642864
CY2022 skgr Cash Withdrawn For Redemptions
CashWithdrawnForRedemptions
0
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
118642864
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-214840000
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
300000
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
300000
CY2023 skgr Proceeds Received From Overfunding Loan
ProceedsReceivedFromOverfundingLoan
0
CY2022 skgr Proceeds Received From Overfunding Loan
ProceedsReceivedFromOverfundingLoan
5240000
CY2023 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2022 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
209600000
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6792000
CY2023 us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
380000
CY2022 us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
0
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
118642864
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5062690
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-118262864
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
216569310
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-351692
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
515410
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
515410
CY2022 skgr Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
170000
CY2023 skgr Deferred Underwriting And Advisory Fees As Noncash Investing And Financing Activities
DeferredUnderwritingAndAdvisoryFeesAsNoncashInvestingAndFinancingActivities
0
CY2022 skgr Deferred Underwriting And Advisory Fees As Noncash Investing And Financing Activities
DeferredUnderwritingAndAdvisoryFeesAsNoncashInvestingAndFinancingActivities
7336000
CY2023 skgr Reversal Of Previous Accrued Offering Costs
ReversalOfPreviousAccruedOfferingCosts
0
CY2022 skgr Reversal Of Previous Accrued Offering Costs
ReversalOfPreviousAccruedOfferingCosts
31985
CY2023 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2021-12-08
CY2022Q2 skgr Total Offering Costs In Connection Within Initial Public Offering
TotalOfferingCostsInConnectionWithinInitialPublicOffering
12000000
CY2022Q2 skgr Deferred Underwriting Commissions
DeferredUnderwritingCommissions
7000000
CY2022Q2 skgr Number Of Days Granted To Underwriters To Subscribe Shares Pursuant To Overallotment Option
NumberOfDaysGrantedToUnderwritersToSubscribeSharesPursuantToOverallotmentOption
P45D
CY2022Q2 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
214800000
CY2022Q2 skgr Per Share Value Of Restricted Asset
PerShareValueOfRestrictedAsset
10.25
CY2023 skgr Businesscombinationconsummateperiodlimit
Businesscombinationconsummateperiodlimit
P185D
CY2023Q4 skgr Percentage Of Public Shares That Can Be Transferred Without Any Restriction
PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction
0.15
CY2023 skgr Percentage Of Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2023Q4 us-gaap Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities
LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
100000
CY2023Q4 us-gaap Share Price
SharePrice
10.25
CY2023Q4 us-gaap Share Price
SharePrice
10.25
CY2023Q4 us-gaap Cash
Cash
163718
CY2023Q4 skgr Working Capital
WorkingCapital
6600000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the financial statements in conformity with <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">U.S.<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. </div>
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2023 skgr Indemnifiable Amounts
IndemnifiableAmounts
5000000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2023 skgr Restricted Investments Term
RestrictedInvestmentsTerm
P185D
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2022Q3 skgr Deferred Underwriting
DeferredUnderwriting
336000
CY2023 skgr Additional Time Frame For Completion Of Business Combination
AdditionalTimeFrameForCompletionOfBusinessCombination
three months each time
CY2023 skgr Underwriting Discount Paid Per Unit
UnderwritingDiscountPaidPerUnit
0.2
CY2023 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
4000000
CY2023 skgr Deferred Underwriting Commission Per Unit
DeferredUnderwritingCommissionPerUnit
0.35
CY2023Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
7000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
one to one
CY2023Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0

Files In Submission

Name View Source Status
0001193125-24-082043-index-headers.html Edgar Link pending
0001193125-24-082043-index.html Edgar Link pending
0001193125-24-082043.txt Edgar Link pending
0001193125-24-082043-xbrl.zip Edgar Link pending
d740922d10k.htm Edgar Link pending
d740922dex311.htm Edgar Link pending
d740922dex312.htm Edgar Link pending
d740922dex32.htm Edgar Link pending
d740922dex321.htm Edgar Link pending
d740922dex322.htm Edgar Link pending
d740922dex971.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g740922g19j28.jpg Edgar Link pending
g740922g45i61.jpg Edgar Link pending
g740922g45r67.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
d740922d10k_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
skgr-20231231.xsd Edgar Link pending
skgr-20231231_def.xml Edgar Link unprocessable
skgr-20231231_lab.xml Edgar Link unprocessable
skgr-20231231_pre.xml Edgar Link unprocessable
skgr-20231231_cal.xml Edgar Link unprocessable